

RÃ³bert SzÃ¡sz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7824074/publications.pdf>

Version: 2024-02-01

19
papers

719
citations

933447

10
h-index

677142

22
g-index

27
all docs

27
docs citations

27
times ranked

866
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10498-10503.	7.1	196
2	Role of Mitochondrial Permeability Transition Pore in Coated-Platelet Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 467-471.	2.4	109
3	MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Scientific Reports, 2016, 6, 31877.	3.3	108
4	Selective Inhibition of the Lectin Pathway of Complement with Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway Activation. Journal of Immunology, 2010, 185, 4169-4178.	0.8	69
5	Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood, 2002, 100, 2827-2831.	1.4	62
6	Coated-platelets retain amyloid precursor protein on their surface. Platelets, 2006, 17, 56-60.	2.3	41
7	COAT platelets. Current Opinion in Hematology, 2003, 10, 351-355.	2.5	34
8	Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. Platelets, 2019, 30, 836-843.	2.3	18
9	Screening and monitoring of the <i>BTK</i> ^{C481S} mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. British Journal of Haematology, 2021, 194, 355-364.	2.5	13
10	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. American Journal of Hematology, 2020, 95, 604-611.	4.1	12
11	Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors. Journal of Biological Chemistry, 2019, 294, 8227-8237.	3.4	11
12	Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment. Platelets, 2013, 24, 486-492.	2.3	8
13	Selectin Expression is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 149-157.	1.5	7
14	Ibrutinib-induced acute kidney injury via interstitial nephritis. Renal Failure, 2021, 43, 335-339.	2.1	7
15	Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia. Scientific Reports, 2020, 10, 16532.	3.3	6
16	Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies. Pathology and Oncology Research, 2021, 27, 1609742.	1.9	4
17	Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis. Scientific Reports, 2022, 12, 7144.	3.3	2
18	Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study). Pathology and Oncology Research, 2019, 25, 535-540.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results. Blood, 2008, 112, 4000-4000.	1.4	0